Xconomist of the Week: Larry Smarr’s Quest for ‘Quantified Health’

monitoring our bodies, noticing deviations from trends, and making appropriate changes.”

I’ve heard Smarr describe CalIT2 as a “time machine” that offers a peek at the future of what IT technologies will be like in 10 years. Now he is providing a similar view into the future of digitally enabled genomic medicine with what he calls “a 10-year detective story of quantifying my body.” He recently agreed to answer a few questions about it.

Xconomy: You didn’t begin this as a scientific odyssey. Yet the extraordinary lengths and level of detail you’ve gone through is amazing. Was it a purely scientific inquiry, or did you feel a personal imperative to find answers to questions about your own health?

Larry Smarr: I really just followed my nose step by step. I started by getting a UCSD trainer and getting back into exercise, which I had neglected for 25 years. Then I read 30 or 40 diet books to better understand nutrition. Once I read Barry Sears, a PhD biochemist and author of the Anti-Aging Zone and related books, I began to realize there was a science of how your body works. That is what began my scientific odyssey.

X: You describe a series of revelations about key blood markers that to you were early warning signals, but were not embraced by your doctors. You also raise serious questions in your paper about the wisdom of taking powerful antibiotics. What were the most significant findings to you?

LS: It never occurred to me that you could easily follow dozens of chemical levels in your blood on a regular basis. Of the 60 or so I track, only one was way out of range, 5 times higher than the recommended upper limit. This was the complex reactive protein (CRP), which is a generic measure of inflammation. What struck me is that I was on a very low inflammatory diet and so how could my CRP be that high? Then I started taking stool samples as well, mainly just to get different chemicals to track. Imagine my surprise when I found my fecal Lactoferrin was 25 times higher than the recommended upper limit! I didn’t know what Lactoferrin was, but thanks to Google, I quickly found out that it was the definitive marker to determine if you had inflammatory bowel disease. When the CRP and Lactoferrin both lined up behind chronic inflammation, I knew I was onto something important.

X: You dryly note that a couple of your doctors called your findings “academic.” But there are no clinical studies that show charting CRP would be an early warning signal for anyone else, right? So how should we think about this?

LS: These are early days in the digital transformation of medicine. Fortunately, medical devices are getting much cheaper and more sensitive, so over the next few years it should become

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.